Pessac

• A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf … Recruiting
  2024-516418-39-00 5 2025-07-09 Multiple Myeloma
• A Study to Evaluate Tobevibart+Elebsiran in Participants with Chronic HDV Infection Not Virologically Suppressed with Bulevirtide Recruiting
  2024-519282-22-00 5 2025-07-09 Chronic Hepatitis D Virus (HDV) Infection
• A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit … Recruiting
  2024-517247-31-00 5 2025-07-07 Newly Diagnosed Higher Risk Myelodysplastic Syndrome
• metastatic colorectal cancer Recruiting
  2023-504831-42-00 5 2025-06-27 patient with colorectal cancer with hepatic metastasis
• A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren’s diseas … Recruiting
  2024-514596-18-00 9 2025-06-20 Difficult to treat rheumatoid arthritis
• Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting
  2024-513122-27-00 5 2025-06-10 Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal … Recruiting
  2024-512302-25-00 5 2025-06-06 Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona … Recruiting
  2024-517457-27-00 5 2025-06-04 Chronic Obstructive Pulmonary Disease (COPD)
• A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's … Recruiting
  2023-509391-42-00 11 2025-06-02 Chron's Disease
• Dose Range Finding Study to Access Efficacy and Safety of Tozorakimab in Adults with Uncontrolled Asthma on Medium-to-High Dose Inhaled Cort … Recruiting
  2024-519116-14-00 4 2025-05-27 Asthma
• ATLANTIS Protamine - Antagonization of heparin with protamine sulfate to reduce all neurologic ischemic and hemorrhagic events after transca … Recruiting
  2023-504511-32-00 5 2025-05-24 Any patients ≥18 years old, eligible for transfemoral TAVI with covera
• Study of lunsekimig (SAR443765) compared with placebo in adults with high-risk asthma Recruiting
  2024-513959-33-00 4 2025-05-13 Asthma
• A Study of Duvelisib Versus the Anti-cancer Drugs Gemcitabine or Bendamustine in Patients With T Cell lymphoma (a type of blood cancer), whi … Recruiting
  2024-516605-23-00 5 2025-05-12 relapsed/refractory nodal T cell lymphoma with T follicular helper (TF
• A Phase 3, multicenter, open label, randomized, non-comparative two-arm study of ivosidenib monotherapy (IVO) and azacitidine monotherapy (A … Recruiting
  2023-510155-37-00 5 2025-05-08 Hypomethylating agent (HMA) naive myelodysplastic syndromes Myelodyspl
• A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinoph … Recruiting
  2024-515162-13-00 5 2025-04-29 Eosinophilic Asthma
• Effect of low-dose arginine-vasopressin supplementation on post-transplant Acute Kidney Injury after liver transplantation - AVENIR Trial Recruiting
  2023-506512-40-00 5 2025-04-16 Acute Kidney Injury
• Evaluation of the benefits of Administering immunosuppressive drugs as Single daily doses over the first Year after liver transplantation Recruiting
  2023-506601-19-00 6 2025-04-15 transplantation
• A Study to Understand the Optimization of the Cytokine Release Syndrome Profile for Glofitamab along with Gemcitabine Plus Oxaliplatin in Pa … Recruiting
  2024-516791-15-00 4 2025-04-08 Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L … Recruiting
  2022-501489-24-00 5 2025-03-28 First-line treatment of adult subjects with high-risk large B-cell lym
• Efficacy and safety of bezafibrate 400 mg and bezafibrate 200 mg as adjunctive treatments in patients with primary biliary cholangitis and n … Recruiting
  2023-504086-23-00 5 2025-03-27 Subjects with PBC with a non-optimal response to UDCA.
• HALT : Influence of Human Albumin supplementation on kidney dysfunction after Liver Transplantation Recruiting
  2024-514804-14-00 6 2025-03-26 Liver transplantation
• MICROBIOTA MODIFICATION FOR IMMUNO-ONCOLOGY IN HEPATOCELLULAR CARCINOMA - “MOTHER” Recruiting
  2023-508201-25-00 4 2025-03-12 Hepatocellular carcinoma
• Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction Recruiting
  2023-508798-94-00 5 2025-02-11 Heart failure
• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca … Recruiting
  2022-502352-31-00 5 2025-02-10 Colorectal Cancer (CRC)

Showing 145–168 of 514 trials